Navigation Links
Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF Presented at American Thoracic Society (ATS)
Date:5/19/2009

- Results suggest pirfenidone may provide meaningful clinical benefit in IPF patients -

- Results of new analyses of efficacy and safety reported -

- Conference Call and Webcast at 9 p.m. EDT (6 p.m. PDT) -

SAN DIEGO, May 19 /PRNewswire-FirstCall/ -- InterMune, Inc. (Nasdaq: ITMN) reported that results from the two Phase 3 CAPACITY studies evaluating pirfenidone in patients with idiopathic pulmonary fibrosis (IPF) were presented today in an oral late-breaker presentation at the International Conference of the American Thoracic Society (ATS) in San Diego. Dr. Paul Noble, co-chair of the CAPACITY program and Professor of Medicine and Chief of Pulmonary, Allergy and Critical Care Medicine at Duke University Medical Center presented details of data from CAPACITY that were previously announced by the company in a press release on February 3, 2009 as well as new information from the studies regarding the efficacy and safety of pirfenidone.

The primary endpoint of change in percent predicted Forced Vital Capacity (FVC) at Week 72 was met with statistical significance in CAPACITY 2 (p=0.001). The secondary endpoints of progression-free survival (PFS) and categorical change in FVC were also met with statistical significance. The primary endpoint was not met in CAPACITY 1 (p=0.501), but supportive evidence of a pirfenidone treatment effect was observed on a number of measures, including the primary endpoint. Pirfenidone was safe and generally well tolerated in both CAPACITY studies. InterMune is preparing a New Drug Application (NDA) expected to be submitted to the FDA in the summer of 2009, to be followed by a Marketing Authorization Application (MAA) submission to the EMEA around the end of 2009.

Dr. Noble commented on the results, "CAPACITY 2 demonstrated a statistic
'/>"/>

SOURCE InterMune, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related medicine technology :

1. Shire Announces Study Results of the Effects of INTUNIV(TM) (Guanfacine) Extended Release on Secondary Measures in Children with ADHD and Oppositional Symptoms
2. Optimer Pharmaceuticals Presents Results From Fidaxomicin Phase 3 Study for the Treatment of Clostridium difficile Infection
3. BioVex to Report Phase I/II Clinical Trial Results for the Front Line Treatment of Head and Neck Cancer With OncoVEX GM-CSF at the 2009 American Society of Clinical Oncology Meeting
4. TYRX Presents Early Clinical Results from AIGISRX(TM) Antibacterial Envelope Retrospective Registry
5. Metabolic Solutions Development Company Announces Preliminary Results from Phase IIa Clinical Trial
6. AlphaVax Announces Promising Results in Melanoma Studies
7. Ongoing Landmark ROADMAP Study Demonstrates Significant Improvement in Blood Pressure Control at One Year, According to Blinded Results
8. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
9. Bionovo Announces First Quarter 2009 Highlights and Financial Results
10. Alexza Reports 2009 First Quarter Financial Results and Updates Clinical Pipeline Status
11. ADVENTRX Announces Results From ANX-514 Bioequivalence Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/17/2014)... 2014  The law firm McElroy, Deutsch, Mulvaney ... will serve as host for "Show Me the ... of Healthcare Reform," a one-day conference scheduled for ... reimbursement, compliance and enforcement in a marketplace re-shaped ... Logo -  http://photos.prnewswire.com/prnh/20140916/146606 Logo -  http://photos.prnewswire.com/prnh/20140916/146607 ...
(Date:9/17/2014)... , Sept. 17, 2014   GS1 ... how to implement GS1 Standards to support the ... enhance patient safety and security in the pharmaceutical ... GS1 Standards to U.S. Pharmaceutical Supply Chain Business ... Act , was developed in collaboration with ...
(Date:9/17/2014)... 2014 Sutro Biopharma, a biopharmaceutical company developing ... division of Merck KGaA, Darmstadt, Germany ... the United States and Canada ... to develop antibody drug conjugates (ADCs). ADCs are composed ... antibody is thought to specifically target and deliver the ...
Breaking Medicine Technology:Three Leading Healthcare Organizations Sponsor Conference to Examine Opportunities and Risks of Healthcare Reform for Providers 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 2New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 3New Healthcare Industry Guideline Delineates How to Implement GS1 Standards to Support Requirements of the 2013 Drug Supply Chain Security Act 4Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 2Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 3Sutro Biopharma and Merck KGaA of Darmstadt, Germany, to Partner on Development of Antibody Drug Conjugates 4
... 13, 2011 ULURU Inc. (NYSE AMEX: ... of intent with Melmed Holdings AG, a company based in Switzerland, ... terms of the agreement ULURU will license the European Union rights ... Altrazeal® in the European Union. In exchange for the license ULURU ...
... Mass., Oct. 12, 2011 NxStage Medical, Inc. (Nasdaq: ... dialysis products, today announced plans to release its financial ... on Thursday, November 3, 2011 before the opening of ... NxStage will also host a conference call at 9:00 ...
Cached Medicine Technology:ULURU Inc. Announces Altrazeal® Agreement for the European Market 2ULURU Inc. Announces Altrazeal® Agreement for the European Market 3NxStage® to Report Third Quarter Fiscal 2011 Financial Results 2
(Date:9/17/2014)... (PRWEB) September 18, 2014 Recently, UWDress.com, ... dresses and women’s special occasion outfits, has released its ... In addition, the firm has launched a big sale ... are now available at deeply discounted rates, from 15 ... that the company insists on using comfortable to wear ...
(Date:9/17/2014)... 2014 According to Centers for ... an estimated 173,285 sports- and recreation-related traumatic brain injuries, ... a blood test may be available to help doctors ... recovery will take. , In March of this ... found a way to test blood for a protein ...
(Date:9/17/2014)... According to an August 5, ... “Adverse Events Associated with Use of Enhancement Medical's ... use of Expression, a hyaluronic acid product, for ... including discoloration, lumps, bruising, nodules, and swelling. ... cosmetic use include Restylane , Juvéderm, Perlane, ...
(Date:9/17/2014)... 2014 Final Cut Pro X plugin developers ... from Pixel Film Studios. , “ProBlue 5k is a compilation ... good to epic,” said Christina Austin, CEO of Pixel Film ... is a definite game changer.” , ProBlue 5k is the ... filmmaker ! This footage compilation of over 100 anamorphic ...
(Date:9/17/2014)... People who struggle to distinguish between a business strategy ... and get the answer by reading Per Wickstrom’s latest blog ... a business plan and a business strategy are both strategic ... “The way I view it is that a business plan ... part two.” , According to the blog post, a ...
Breaking Medicine News(10 mins):Health News:2014 Empire Waist Evening Dress Collection Now Unveiled At UWDress.com 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 2Health News:Breakthrough blood test will improve concussion diagnoses, treatment 3Health News:Simon Ourian, Kim Kardashian's Cosmetic Surgeon, Warns About Illegal Use of Expression as a Dermal Filler 2Health News:A New Plugin Entitled ProBlue 5k Was Released Today from Pixel Film Studios Exclusively for Final Cut Pro X 2Health News:Per Wickstrom’s Latest Blog Explores the Difference Between a Business Plan and a Business Strategy 2
... ... , ... April 19, 2010 -- ORCS Web Inc., a specialist in Microsoft Windows-based internet hosting ... newly released ASP .NET 4.0 has been made available on all of their ...
... ... to age gracefully and maintain healthy skin? Here are 35 articles that cover the full ... any age, makeup tips for mature skin and the details on effective ingredients. , ... (PRWEB) April 19, 2010 -- Aging ...
... ... Institute is penetrating major metropolitan areas with its high-demand, proactive medical approach that optimizes ... ... Medical Institute , global age management medicine leader, is meeting the healthy aging boom ...
... ... the 40th Earth Day. The first Earth Day was held in 1970 and is widely seen ... ... join the worldwide community in celebrating the 40th Earth Day. The first Earth Day was held ...
... at the Medical College of Wisconsin and Children,s Hospital ... have found that many metropolitan Milwaukee child care directors ... Andrew N. Hashikawa, M.D., and colleagues surveyed 305 child ... directors followed national guidelines from the American Academy of ...
... Treatment may be used one day as part of cancer-fighting ... April 18 (HealthDay News) -- A new study in mice ... cells could become a target for cancer vaccines. , A ... transcription) of genetic material from the DNA to messenger RNA. ...
Cached Medicine News:Health News:ORCS Web, Inc Supports ASP .NET 4.0 2Health News:Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging 2Health News:Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging 3Health News:Anti-Aging Handbook: Top 35 Articles on Treating and Preventing Signs of Aging 4Health News:Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building 2Health News:Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building 3Health News:Global Leader Readied For Healthy Aging Boom, Targets Wall Street With New Center In Trump Building 4Health News:Ecco Bella, A Natural Beauty and Skin Care Company, Celebrates Earth Day 2010 2Health News:Day care dilemma: When 'sick' children are unnecessarily sent home 2Health News:Vaccine Stops Tumor Spread in Mice 2
Sealing tape, white Rayon, breathable, NS...
Amplification Tape 96 featuring 3M adhesive technology. Good optical quality. Minimal autofluorescence. Certified RNase and DNase free....
Sealing tape featuring 3M adhesive technology. Compatible with DMSO. Good optical quality. Minimal autofluorescence....
Thermal Seal, Clear, Bulk...
Medicine Products: